Ronovo Surgical has received regulatory approval for its Carina surgical robotic platform in China. Shanghai-based Ronovo develops broad, cross-specialty robotic-assisted surgery (RAS) technology. It unveiled the Carina platform in February 2023 as a modular system built on proprietary technology to enable configurable robotic assistance for laparoscopic surgeries across multiple specialties.
Carina addresses numerous pain points in minimally invasive surgeries. The company says it provides surgeons with the flexibility to choose the best instruments and the most ideal anatomical access.
Related: Cerus secures CE mark approval for LED-based illumination device
Last June, the company raised $46 million, with eyes on bringing the robot to the market in China.
The approval covers the platform for use in urologic, gynecologic, thoracic and general surgery in China. Carina becomes the latest surgical robotic platform to receive approval in China as more medtech platforms make their way to the region. Other examples include J&J’s Monarch, which became the first minimally invasive, robotic-assisted technology approved for peripheral lung procedures in China in 2023 and Stereotaxis received approval for its Genesis robot last year. Market leader Intuitive also continues to grow in China.
“This marks a pivotal moment in our mission to democratize robotic surgery, making it more accessible and adaptable to diverse healthcare settings worldwide,” Ronovo Surgical said in a post. “By overcoming limitations of conventional robotic surgery systems, we are enabling more hospitals and surgeons to unlock the potential of robotic-assisted surgery.”
